Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 76 results for acute coronary syndromes

  1. Familial hypercholesterolaemia: identification and management (CG71)

    This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

    Clinical guideline
    Last updated
    4 October 2019
    View recommendations

    Sections for CG71

  2. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

    Technology appraisal guidance
    Last updated
    18 November 2020
    View recommendations

    Sections for TA152

  3. Intra-aortic balloon counter‑pulsation: In people with acute heart failure and hypoperfusion syndrome, is the use of intra‑aortic balloon counter‑pulsation pump (IABP) better than the use of intravenous inotropes?

    Intra-aortic balloon counter‑pulsation: In people with acute heart failure and hypoperfusion syndrome, is the use of...

    Research recommendation
    Published
    16 December 2021

  4. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    23 March 2023
    View quality statements

    Sections for QS76

  5. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

    NICE guideline
    Last updated
    13 August 2019
    View recommendations

    Sections for NG89

  6. What is the most clinically and cost-effective dual antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention (PCI)?

    therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous...

    Research recommendation
    Published
    22 January 2021

  7. Past appeals and decisions

    Past technology appraisal appeals and decisions

  8. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA236

  9. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

    Medtech innovation briefing
    Published
    2 February 2021

  10. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

    Medtech innovation briefing
    Published
    11 March 2016

  11. Cardiometabolic disease prevention and treatment guidelines

    Abdominal aortic aneurysm: diagnosis and management Acute coronary syndromes - Acute heart failure: diagnosis and...

    NICE guideline
    In development

  12. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

    HealthTech guidance
    Published
    4 December 2025
    View recommendations

    Sections for HTG761

  13. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Last updated
    1 March 2010
    View recommendations

    Sections for TA47

  14. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

    HealthTech guidance
    Last updated
    1 October 2018
    View recommendations

    Sections for HTG326

  15. Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)

    Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.

    HealthTech guidance
    Published
    6 May 2025
    View recommendations

    Sections for HTG747